Skip to main content
Article thumbnail
Location of Repository

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

By Leslie Citrome


Aripiprazole has been approved by regulatory agencies for the treatment of schizophrenia and bipolar I disorder. Although it is a dopamine partial agonist, it also has substantial binding affinity for the serotonin 5HT2A receptor. Several double-blind randomized clinical trials have established the efficacy and tolerability of aripiprazole within the dose range of 10–30 mg/day for schizophrenia, and 15–30 mg/day for manic or mixed states associated with bipolar I disorder. Relatively few comparative trials with other second-generation antipsychotics have been published for schizophrenia, with none available for bipolar disorder. The evidence so far suggests that in terms of efficacy for schizophrenia, aripiprazole is superior to placebo and haloperidol (long term), similar to perphenazine and risperidone, and inferior to olanzapine. Its tolerability profile in patients with schizophrenia appears superior to haloperidol, perphenazine, risperidone, and olanzapine. Efficacy in treating manic or mixed states was established in placebo-controlled trials. Among some patients with bipolar disorder, akathisia and gastrointestinal (GI) complaints can emerge at the start of treatment; however, the GI symptoms were time-limited in many instances. Appropriate dosing may also be important in individualizing therapy to improve tolerability, with lower starting doses becoming more important when adding to, or switching from, another antipsychotic. Aripiprazole appears to have a low propensity for weight gain, a favorable metabolic profile, and no association with hyperprolactinemia

Topics: Expert Opinion
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2004). A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
  2. (2003). A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.
  3. (2006). A randomized, doubleblind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.
  4. (2006). Abilify (aripiprazole tablets and oral solution).
  5. (2006). An exploratory openlabel trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand,
  6. (2004). Aripiprazole – A review of its use in schizophrenia and schizoaffective disorder.
  7. Aripiprazole and atypical neuroleptic malignant syndrome.
  8. (2004). Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol,
  9. (2006). Aripiprazole as a dopamine partial agonist.
  10. Aripiprazole for acute bipolar mania.
  11. (2005). Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignat syndrome.
  12. (2003). Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
  13. (2004). Aripiprazole in acute mania associated with bipolar I disorder.
  14. (2005). Aripiprazole in schizophrenia: consensus guidelines.
  15. (2006). Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo controlled study.
  16. (2004). Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol,
  17. (2003). Aripiprazole vs perphenazine in treatment-resistant schizophrenia. 156th Annual Meeting of the American Psychiatric Association.
  18. (2004). Aripiprazole-olanzapine combination for treatment of schizophrenia.
  19. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.
  20. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
  21. (2003). Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry,
  22. (2004). Atypical antipsychotics: matching receptor profile to individual patient’s clinical profile.
  23. (2006). Clozapine augmentation with aripiprazole for negative symptoms. J Clin Psychiatry, 67:674– 5. De Deyn
  24. (2001). CN138-001: A multicenter, randomized, double-blind, placebo controlled study of three fixed doses of aripiprazole in the treatment of patients with acute schizophrenia [online].
  25. (2004). CN138-002 (26-52 week): A multicenter, randomized, double-blind safety and tolerability study of flexible doses of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia [online].
  26. (2005). CN138-003: A multicenter, double-blind, randomized comparative study of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia [online].
  27. (2004). CN138-032: A multicenter, randomized, double-blind study of flexible doses of aripiprazole vs perphenazine in the treatment of patients with treatment-resistant schizophrenia [online].
  28. (2004). CN138-047: A multicenter, randomized, double-blind, placebo controlled, 26 week study of a fixed dose of aripiprazole in the treatment of stabilized patients with chronic schizophrenia: open-label randomized, 52 week extension phase [online].
  29. (2004). CN138-087: A prospective, multicenter, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practices [online]
  30. (2005). Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia.
  31. (1998). Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?
  32. (2005). Dosing of quetiapine in schizophrenia – how clinical practice differs from registration studies.
  33. (2005). Dosing of second-generation antipsychotic medication in a state hospital system.
  34. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
  35. (2005). Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial.
  36. (2001). Effectiveness of secondgeneration antipsychotics in patients with treatment resistant schizophrenia: A review and meta-analysis of randomized trials.
  37. (2002). Efficacy and safety of aripiprazole and haloperidol vs placebo in patients with schizophrenia and schizoaffective disorder.
  38. (2003). Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.
  39. (2002). Essential psychopharmacology of antipsychotics and mood stabilizers. New York:
  40. (1999). Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials.
  41. (2004). for schizophrenia. Cochrane Database Syst Rev,
  42. (2005). Galactorrhea with aripiprazole.
  43. (2006). High-dose aripiprazole in treatmentresistant schizophrenia.
  44. (2002). Managing treatment-resistant schizophrenia: evidence from randomized clinical trials.
  45. (2002). Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry,
  46. (2005). Pharmacokinetics of aripiprazole and concomitant lithium and valproate.
  47. (2004). Possible increased efficacy of lowdose clozapine when combined with aripiprazole.
  48. (2005). Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine.
  49. (2002). Safety and tolerability of aripiprazole at doses higher than 30 mg [abstract].
  50. (2005). Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry,
  51. (2003). Supplemental new drug application submitted for ABILIFY(TM) (aripiprazole) for the treatment of acute bipolar mania [online].
  52. (2005). Towards convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry,
  53. (2005). Treatment-emergent psychosis with aripiprazole.
  54. (2006). Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.
  55. (2005). What makes aripiprazole the different antipsychotic. Current Psychiatry,
  56. (2004). Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism?
  57. (2004). Worsening schizoaffective disorder with aripiprazole.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.